Clinical Trials on Urticaria in Japan

Total 37 results

Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients

Chronic Spontaneous Uriticaria

Korea, Republic of, Japan
Taiho Pharmaceutical Co., Ltd.

Recruiting

A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

Japan
Novartis Pharmaceuticals

Completed

A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines

Chronic Spontaneous Urticaria

Japan
Novartis Pharmaceuticals

Completed

A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines (BISCUIT)

Chronic Spontaneous Urticaria

Japan
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)

Chronic Spontaneous Urticaria

United States, Canada, Japan
Novartis Pharmaceuticals

Completed

Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU

Chronic Spontaneous Urticaria

United States, Spain, United Kingdom, Germany, Taiwan, Japan, Australia, Greece, Russian Federation, Canada
Novartis Pharmaceuticals

Completed

A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

Chronic Spontaneous Urticaria

United States, Spain, Germany, Taiwan, Japan, Australia, Russian Federation, Greece, Canada, United Kingdom
AstraZeneca
Iqvia Pty Ltd

Terminated

A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO) (ARROYO)

Chronic Spontaneous Urticaria

United States, Germany, Korea, Republic of, Spain, Bulgaria, Poland, Japan
Sanofi

Completed

Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine (RILECSU)

Chronic Spontaneous Urticaria

Chile, Taiwan, Argentina, Germany, Canada, Russian Federation, Netherlands, Korea, Republic of, Spain, Greece, Italy, Japan, Poland
Novartis Pharmaceuticals

Completed

This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines

Chronic Spontaneous Urticaria

United States, Belgium, United Kingdom, Germany, Hungary, Spain, France, Turkey, Canada, Czechia, Netherlands, Poland, Japan, Russian Federation, Argentina, Denmark, Slovakia
Novartis Pharmaceuticals

Recruiting

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Chronic Spontaneous Urticaria

United States, Singapore, Spain, Germany, Turkey, Italy, Hong Kong, China, Argentina, Malaysia, Thailand, Poland, Japan, Netherlands, South Africa, Chile, Canada
Amgen

Completed

Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria (INCEPTION)

Chronic Spontaneous Urticaria

United States, Korea, Republic of, Spain, Italy, Canada, Poland, Japan, France, Greece, Germany
Novartis Pharmaceuticals

Completed

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines (REMIX-1)

Chronic Spontaneous Urticaria

United States, Hungary, Taiwan, Spain, Italy, Korea, Republic of, Australia, France, Bulgaria, Czechia, Turkey, India, Argentina, Mexico, Japan, Colombia, Russian Federation, Puerto Rico, Singapore
Novartis Pharmaceuticals

Completed

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU

Chronic Spontaneous Urticaria

United States, Belgium, United Kingdom, Hungary, Spain, France, Turkey, Canada, Czechia, Russian Federation, Poland, Japan, Argentina, Denmark, Slovakia
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

Chronic Spontaneous Urticaria

China, France, Spain, Argentina, Germany, Japan, United States, Canada, Hungary, Russian Federation, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)

Cold Urticaria

United States, Argentina, Canada, Germany, Japan
Novartis Pharmaceuticals

Completed

A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

Chronic Spontaneous Urticaria

United States, Poland, Spain, Belgium, Germany, Russian Federation, Taiwan, Netherlands, Italy, Australia, France, Israel, Lebanon, Slovakia, India, Japan, Estonia, Philippines, Mexico, Argentina, United Kingdom, Vietnam, Brazil, Romania and more
Novartis Pharmaceuticals

Recruiting

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Chronic Spontaneous Urticaria

United States, Korea, Republic of, Spain, France, Germany, Bulgaria, United Kingdom, China, Hungary, Czechia, Turkey, Argentina, Colombia, Italy, Denmark, Japan, Taiwan, Australia, Singapore, Switzerland, Russian Federation, Thailand and more
Novartis Pharmaceuticals

Recruiting

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Chronic Inducible Urticaria

China, United States, Australia, Korea, Republic of, Israel, Turkey, Hong Kong, Japan, Argentina, Malaysia, Singapore, Thailand, Canada
Takeda

Recruiting

A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema

Hereditary Angioedema (HAE)

Japan
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

Chronic Spontaneous Urticaria

United States, Spain, Belgium, Croatia, Germany, Hungary, India, Malaysia, Russian Federation, Taiwan, Turkey, Netherlands, Italy, Australia, Israel, Korea, Republic of, Lebanon, Greece, Singapore, Slovakia, Thailand, Austria, Bulgaria and more
Takeda

Recruiting

A Survey of Lanadelumab in Participants With Hereditary Angioedema

Hereditary Angioedema (HAE)

Japan
Takeda

Completed

A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema

Hereditary Angioedema

Japan
Shire

Completed

A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants

Hereditary Angioedema (HAE)

Japan
BioCryst Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan (APeX-J)

Hereditary Angioedema, HAE

Japan
Takeda

Completed

Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema

Hereditary Angioedema

Japan
Shire

Completed

Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

Japan
Shire
Takeda

Completed

FIRAZYR General Drug Use-Results Survey (Japan)

Hereditary Angioedema (HAE)

Japan
Shire

Completed

Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

Japan
CSL Behring

Completed

CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

Hereditary Angioedema

United States, Germany, Japan, Hungary, Canada, Netherlands, Israel
CENTOGENE GmbH Rostock

Completed

Epidemiological Analysis for Hereditary Angioedema Disease (EHA)

Abdominal Pain | Functional Abdominal Pain

United Kingdom, Germany, Turkey, Poland, Italy, Japan
Shire
Takeda Development Center Americas, Inc.

Completed

A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Angioedema

United States, France, Netherlands, Spain, Hungary, Italy, Canada, Poland, Japan, Germany
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Angioedema

United States, Spain, Netherlands, Hungary, Italy, Canada, Germany, France, Japan, Poland
CSL Behring

Active, not recruiting

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

Hereditary Angioedema

Australia, Canada, United States, New Zealand, Germany, Hong Kong, Netherlands, Taiwan, Czechia, Israel, Hungary, Japan, Russian Federation, Spain
KalVista Pharmaceuticals, Ltd.

Recruiting

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Hereditary Angioedema

United States, Bulgaria, France, Greece, Israel, Netherlands, Spain, United Kingdom, Australia, Germany, South Africa, Slovakia, Austria, New Zealand, Romania, Canada, Japan
KalVista Pharmaceuticals, Ltd.

Completed

A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Hereditary Angioedema

United States, Australia, Bulgaria, Canada, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, North Macedonia, Poland, Portugal, Puerto Rico, Romania, Slovakia, Spain, United Kingdom
KalVista Pharmaceuticals, Ltd.

Recruiting

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Hereditary Angioedema

United States, Bulgaria, France, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, North Macedonia, Poland, Spain, United Kingdom, Australia, Germany, South Africa, Austria, Portugal, Slovakia, Romania, Canada, Saudi Arabia, Japa...

Clinical Trials on Urticaria in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations